NASDAQ:RETA
Delisted
RETA Stock News
$172.36
+0 (+0%)
At Close: Dec 22, 2023
Reata: Blooming With Orphans
01:32am, Friday, 05'th Jul 2019
Orphan (i.e., rare) disease used to be a barren investment field until Henri Termeer took activism to U.S. Congress. His work ultimately puts forward incentives for orphan drug innovators.
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
10:29am, Thursday, 06'th Jun 2019
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2019 Results - Earnings Call Transcript
02:31pm, Thursday, 09'th May 2019
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2019 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates
07:55am, Thursday, 09'th May 2019
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.03% and -1.94%, respectively, for the quarter ended March 2019.
Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference
03:26pm, Monday, 06'th May 2019
Bihua Chen, founder and portfolio manager at Cormorant Asset Management, said on Monday she likes kidney disease drugmaker Reata Pharmaceutical.
Reata CEO on drug that shows signs of reversing kidney damage
03:33pm, Tuesday, 02'nd Apr 2019
Reata CEO Warren Huff discusses his company's new drug, which has shown signs it can reverse kidney damage.
